Novel targeted therapies like HSP inducers, including GGA and its derivatives—which may upregulate HSP expression by activating HSF-1 and enhancing its binding to HSEs in HSP gene promoter regions—could represent a paradigm shift in AF treatment. This evidence concerns the gene HSF1 and atrial fibrillation.